Literature DB >> 28462873

Maternal obesity and obstetric outcomes in a tertiary referral center.

Gitana Ramonienė1, Laima Maleckienė2, Rūta Jolanta Nadišauskienė1, Eglė Bartusevičienė1, Dalia Regina Railaitė1, Regina Mačiulevičienė1, Almantas Maleckas3.   

Abstract

BACKGROUND AND AIM: Obese women are at an increased risk of various adverse pregnancy outcomes. The aim of our study was to evaluate the impact of obesity on maternal and neonatal outcomes in a tertiary referral center and to compare obstetric outcomes by the level of maternal obesity.
MATERIALS AND METHODS: A cohort study included 3247 women with singleton gestations who gave birth at the Department of Obstetrics and Gynecology, Lithuanian University of Health Sciences, in 2010. Pregnancy complications and neonatal outcomes were identified using the hospital Birth Registry database in normal weight (body mass index [BMI] 18.5-24.9kg/m2, n=3107) and prepregnancy obese (BMI ≥30kg/m2, n=140) women. Pregnancy outcomes were compared according to the level of obesity (BMI 30-34.9kg/m2, n=94 and BMI ≥35kg/m2, n=46).
RESULTS: Obese women were significantly more likely to have gestational hypertension (OR=8.59; 95% CI, 5.23-14.14; P<0.0001), preeclampsia (OR=2.06; 95% CI, 1.14-3.73; P<0.0001), gestational diabetes (OR=5.56; 95% CI, 3.66-8.49; P<0.0001), dystocia (OR=2.14; 95% CI, 1.36-3.38; P<0.0001), induced labor (OR=2.64; 95% CI, 1.83-3.80; P<0.0001), failed induction of labor (OR=18.06; 95% CI, 8.85-36.84; P<0.0001), cesarean delivery (OR=1.76; 95% CI, 1.25-2.49; P=0.001), large-for-gestational-age newborns (OR=3.68; 95% CI, 2.51-5.39; P<0.0001). Significantly increased risk of gestational diabetes, preeclampsia, dystocia and newborns with Apgar score ≤7 after 5min was only observed in women with BMI ≥35kg/m2.
CONCLUSIONS: Maternal obesity is significantly associated with an increased risk of gestational hypertension, preeclampsia, gestational diabetes, dystocia, labor induction, failed induction of labor, large-for-gestational-age newborns and cesarean delivery.
Copyright © 2017 The Lithuanian University of Health Sciences. Production and hosting by Elsevier Sp. z o.o. All rights reserved.

Entities:  

Keywords:  Cesarean delivery; Gestational diabetes; Large-for-gestational-age newborn; Obesity; Pregnancy

Mesh:

Year:  2017        PMID: 28462873     DOI: 10.1016/j.medici.2017.03.003

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  6 in total

1.  Hospital breastfeeding support and exclusive breastfeeding by maternal prepregnancy body mass index.

Authors:  Laura R Kair; Nathan C Nickel; Krista Jones; Katelin Kornfeind; Heather L Sipsma
Journal:  Matern Child Nutr       Date:  2019-02-27       Impact factor: 3.092

2.  Obstetric outcomes during delivery hospitalizations among obese pregnant women in the United States.

Authors:  Muni Rubens; Venkataraghavan Ramamoorthy; Anshul Saxena; Peter McGranaghan; Emir Veledar; Agueda Hernandez
Journal:  Sci Rep       Date:  2022-04-27       Impact factor: 4.996

3.  A Case-Control Study of the APELA Gene and Hypertensive Disorders of Pregnancy.

Authors:  Naomi Shimada; Tomohiro Nakayama; Hiroshi Umemura; Kei Kawana; Tatsuo Yamamoto; Seisaku Uchigasaki
Journal:  Medicina (Kaunas)       Date:  2022-04-26       Impact factor: 2.948

4.  Pre-Pregnancy Obesity, Excessive Gestational Weight Gain, and the Risk of Pregnancy-Induced Hypertension and Gestational Diabetes Mellitus.

Authors:  Małgorzata Lewandowska; Barbara Więckowska; Stefan Sajdak
Journal:  J Clin Med       Date:  2020-06-24       Impact factor: 4.241

Review 5.  Fetal Growth Acceleration-Current Approach to the Big Baby Issue.

Authors:  Jan Modzelewski; Anna Kajdy; Katarzyna Muzyka-Placzyńska; Dorota Sys; Michał Rabijewski
Journal:  Medicina (Kaunas)       Date:  2021-03-02       Impact factor: 2.430

6.  Gestational Diabetes Mellitus in Europe: A Systematic Review and Meta-Analysis of Prevalence Studies.

Authors:  Marília Silva Paulo; Noor Motea Abdo; Rita Bettencourt-Silva; Rami H Al-Rifai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.